Randomized Evaluation of Long term anticoagulant therapy comparing the efficacy and safety of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation
Description of Research
Patients with atrial fibrillation who are at a high risk of stroke may take a blood-thinning medication to reduce the risk of stroke. The purpose of this study is to evaluate how well Dabigatran etexilate works (at two different doses) and how safe it is, compared to warfarin, which is standard therapy for patients with atrial fibrillation.
Age 18 years or older
Documented atrial fibrillation
Must have additional risk factors for stroke
Additional screening criteria